Therapeutic approaches to vascular protection in ischemic stroke

Acta Medica Okayama

Volumn 65, Issue 4, 2011, Pages 219-223

  Yamashita, Toru ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cerebral ischemia; Free radical; Hemorrhagic transformation; Matrix metalloproteinase 9; Tissue plasminogen activator

Indexed keywords

GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; BLOOD BRAIN BARRIER; BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ANIMALS; BLOOD VESSELS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; HUMANS; INTRACRANIAL HEMORRHAGES; MATRIX METALLOPROTEINASE 9; SIGNAL TRANSDUCTION; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80052683687     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The national institute of neurological disorders and stroke rt-pa stroke study group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333: 1581-1587.
2. The ninds t-pa stroke study group: Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke (1997) 28: 2109-2118.
3. del Zoppo GJ: Stroke and neurovascular protection. N Engl J Med (2006) 354: 553-555.
4. Adibhatla RM and Hatcher JF: Tissue plasminogen activator (tpa) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol Disord Drug Targets (2008) 7: 243-253.
5. Jin R, Yang G and Li G: Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells. J Leukoc Biol (2010) 87: 779-789.
6. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, Chamorro A and Planas AM: Neutrophil infiltration increases matrix metallopro-teinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab (2003) 23: 1430-1440.
7. McColl BW, Rothwell NJ and Allan SM: Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci (2008) 28: 9451-9462.
8. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME and Lo EH: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci (2001) 21: 7724-7732.
9. Lee CZ, Xue Z, Zhu Y, Yang GY and Young WL: Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke (2007) 38: 2563-2568.
10. Yang Y, Estrada EY, Thompson JF, Liu W and Rosenberg GA: Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab (2007) 27: 697-709.
11. Clark AW, Krekoski CA, Bou SS, Chapman KR and Edwards DR: Increased gelatinase a (mmp-2) and gelatinase b (mmp-9) activities in human brain after focal ischemia. Neurosci Lett (1997) 238: 53-56.
12. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M and Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation (2003) 107: 598-603.
13. Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J and Davalos A: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke (2007) 38: 1855-1859.
14. Chan PH: Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab (2001) 21: 2-14.
15. Maier CM, Hsieh L, Crandall T, Narasimhan P and Chan PH: Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol (2006) 59: 929-938.
16. Goto H, Fujisawa H, Oka F, Nomura S, Kajiwara K, Kato S, Fujii M, Maekawa T and Suzuki M: Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J Neurotrauma (2007) 24: 745-752.
17. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J and Lo EH: Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke (2005) 36: 1954-1959.
18. Herz J and Strickland DK: Lrp: A multifunctional scavenger and signaling receptor. J Clin Invest (2001) 108: 779-784.
19. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D and Yepes M: Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood (2007) 109: 3270-3278.
20. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J, Chuquet J, Nouvelot A, MacKenzie ET, Bu G, Cecchelli R, Touzani O and Vivien D: Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation (2005) 111: 2241-2249.
21. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW and Lo EH: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med (2003) 9: 1313-1317.
22. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M and Zlokovic BV: Activated protein c inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 12: 1278-1285.
23. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, Miyazaki K, Ohtsuka A, Katayama Y and Abe K: Dissociation and protection of the neurovascular unit after thrombolysis and reperfu-sion in ischemic rat brain. J Cereb Blood Flow Metab (2009) 29: 715-725.
24. Edaravone Acute Infarction Study Group: Effect of a novel free radical scavenger, edaravone (mci-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis (2003) 15: 222-229.
25. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG and Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT) Trial Investigators: Nxy-059 for acute ischemic stroke. N Engl J Med (2006) 354: 588-600.
26. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW and Emeribe U; SAINT II Trial Investigators: Nxy-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 357: 562-571.
27. Yamamoto Y KT, Watanabe K, Watanabe K: Antioxidant activity of 3-methyl-l-phenyl-2-pyrazolin-5-one. Redox Rep (1996) 2: 333-338.
28. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U and Lawrence DA: Activation of pdgf-cc by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 14: 731-737.
29. HungYC, Chen TY, Lee EJ, Chen WL, Huang SY, Lee WT, Lee MY, Chen HY and Wu TS: Melatonin decreases matrix metallo proteinase-9 activation and expression and attenuates reperfusion-induced hemorrhage following transient focal cerebral ischemia in rats. J Pineal Res (2008) 45: 459-467.
30. Sumii T and Lo EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 33: 831-836.
31. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X and Lo EH: Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 39: 3372-3377.
32. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R and Zivin JA: Effects of the spin trap agent disodium- [(tert-butylimino) methyl] benzene-1, 3-disulfonate n-oxide (generic nxy-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: Combination studies with tissue plasminogen activator. Stroke (2002) 33: 1665-1670.